Market Cap (In USD)
21.49 Million
Revenue (In USD)
-
Net Income (In USD)
-8.35 Million
Avg. Volume
27.47 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 5.4-32.55
- PE
- -
- EPS
- -
- Beta Value
- 0.0
- ISIN
- US1276361086
- CUSIP
- CIK
- 1937993
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Quang X. Pham
- Employee Count
- -
- Website
- https://www.cadrenal.com
- Ipo Date
- 2023-01-20
- Details
- Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
More Stocks
-
CUMMINSINDCummins India Limited
CUMMINSIND
-
INDSWFTLTDInd-Swift Limited
INDSWFTLTD
-
KST
-
AND
-
0GZVGetinge AB (publ)
0GZV
-
300960
-
SPKSJFSparekassen Sjælland-Fyn A/S
SPKSJF
-
0RH1Kinnevik AB
0RH1